Selected Grants
DRA02 - A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)
Clinical TrialPrincipal Investigator · Awarded by Allogene Therapeutics, Inc. · 2025 - 2035JASMINE
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2031A Longitudinal Tele-Education Program in Myositis
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Priovant Therapeutics, Inc · 2025 - 2027Arthritis Foundation - DEI
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Arthritis Foundation · 2022 - 2025RRF - Amgen Fellowship Training Award
FellowshipPrincipal Investigator · Awarded by Rheumatology Research Foundation · 2023 - 2024Moving the ACR's Reproductive Health Guidelines into Practice
ResearchEducation Director · Awarded by Rheumatology Research Foundation · 2021 - 2024Clinician Scholar Educator Award
ResearchMentor · Awarded by Rheumatology Research Foundation · 2018 - 2022Amgen Fellowship Training Award
FellowshipPrincipal Investigator · Awarded by Rheumatology Research Foundation · 2017 - 2018Training Program in Inflammatory and Immunological Diseases
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1980 - 2017Determinants of ANA Expression in Patients with SLE
ResearchInvestigator · Awarded by Lupus Research Institute · 2015 - 2017RRF Amgen Fellowship Training Award FY 2015
FellowshipPrincipal Investigator · Awarded by Rheumatology Research Foundation · 2014 - 2015PEG-uricase as Therapy for Refractory Gout IND#11274
ResearchCo Investigator · Awarded by Food and Drug Administration · 2004 - 2009External Relationships
- Conference reporter
- Up To Date Inc/Wolters Kluwer Health
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.